David Borg

4.9k total citations
20 papers, 617 citations indexed

About

David Borg is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Borg has authored 20 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 13 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Borg's work include Gastric Cancer Management and Outcomes (12 papers), Esophageal Cancer Research and Treatment (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). David Borg is often cited by papers focused on Gastric Cancer Management and Outcomes (12 papers), Esophageal Cancer Research and Treatment (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). David Borg collaborates with scholars based in Sweden, Denmark and Ireland. David Borg's co-authors include Charlotta Hedner, Karin Jirström, Björn Nodin, Fredrik Holmquist, Bodil Andersson, Monika Bauden, Roland Andersson, Agata Sasor, Daniel Ansari and Bobby Tingstedt and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

David Borg

17 papers receiving 610 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Borg Sweden	12	391	194	177	164	141	20	617
Alexander G. Raufi United States	11	275 0.7×	156 0.8×	140 0.8×	111 0.7×	61 0.4×	36	457
Hisahito Endo Japan	11	256 0.7×	206 1.1×	127 0.7×	119 0.7×	151 1.1×	30	532
Paul Mansfield United States	10	300 0.8×	211 1.1×	201 1.1×	168 1.0×	83 0.6×	18	630
Chunhui Zhang China	13	324 0.8×	210 1.1×	102 0.6×	112 0.7×	184 1.3×	31	650
Ertao Zhai China	14	195 0.5×	350 1.8×	147 0.8×	95 0.6×	68 0.5×	30	605
Jianling Zou China	14	243 0.6×	200 1.0×	119 0.7×	65 0.4×	64 0.5×	18	467
Ruixuan Geng China	12	254 0.6×	234 1.2×	196 1.1×	58 0.4×	66 0.5×	29	556
A. Reinacher-Schick Germany	11	441 1.1×	175 0.9×	146 0.8×	93 0.6×	61 0.4×	46	636
Hongbing Shi China	12	321 0.8×	159 0.8×	167 0.9×	80 0.5×	204 1.4×	25	626
Yu Heng China	15	200 0.5×	212 1.1×	140 0.8×	177 1.1×	113 0.8×	59	651

Countries citing papers authored by David Borg

Since Specialization

Citations

This map shows the geographic impact of David Borg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Borg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Borg more than expected).

Fields of papers citing papers by David Borg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Borg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Borg. The network helps show where David Borg may publish in the future.

Co-authorship network of co-authors of David Borg

This figure shows the co-authorship network connecting the top 25 collaborators of David Borg. A scholar is included among the top collaborators of David Borg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Borg. David Borg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Παπαδάκος, Κωνσταντίνος Σ., Chrysostomi Gialeli, Charlotta Hedner, et al.. (2024). The prognostic and potentially immunomodulatory role of cartilage oligomeric matrix protein in patients with gastric and esophageal adenocarcinoma. Cancer Immunology Immunotherapy. 73(5). 93–93.

Tsekrekos, Andrianos, David Borg, Magnus Nilsson, et al.. (2023). Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide Study. Annals of Surgical Oncology. 30(12). 7196–7205. 2 indexed citations

Nodin, Björn, David Borg, Charlotta Hedner, et al.. (2022). High Infiltration of CD68<sup>+</sup>/CD163<sup>−</sup> Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma. Journal of Innate Immunity. 14(6). 615–628. 12 indexed citations

Sheehan, Katherine M., Elaine W. Kay, Charlotta Hedner, et al.. (2021). Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers. Cancers. 13(6). 1286–1286.

Borg, David, et al.. (2021). T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival. OncoImmunology. 10(1). 1921443–1921443. 18 indexed citations

Borg, David, Charlotta Hedner, Björn Nodin, et al.. (2020). Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma. Frontiers in Oncology. 10. 534761–534761. 28 indexed citations

Borg, David, Cheng Zhang, Charlotta Hedner, et al.. (2019). Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. Frontiers in Oncology. 9. 136–136. 34 indexed citations

Borg, David, J. Sundberg, Eva Brun, et al.. (2019). Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial. Acta Oncologica. 59(2). 212–218. 4 indexed citations

Borg, David, Anna Larsson, Charlotta Hedner, et al.. (2018). Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. Journal of Translational Medicine. 16(1). 290–290. 7 indexed citations

10.

Hedner, Charlotta, et al.. (2018). Prognostic significance of lymphocyte-activation gene-3 expression in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma. Annals of Oncology. 29. viii220–viii220. 6 indexed citations

11.

Hedner, Charlotta, David Borg, Björn Nodin, et al.. (2017). Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. Journal of Clinical Pathology. 71(5). 451–462. 9 indexed citations

12.

Hedner, Charlotta, David Borg, Jakob Eberhard, et al.. (2017). The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget. 8(42). 72108–72126. 50 indexed citations

13.

Borg, David, Charlotta Hedner, Björn Nodin, et al.. (2016). Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clinical Pathology. 16(1). 13–13. 27 indexed citations

14.

Borg, David, Charlotta Hedner, Alexander Gaber, et al.. (2016). Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomarker Research. 4(1). 10–10. 26 indexed citations

15.

Hedner, Charlotta, David Borg, Björn Nodin, et al.. (2016). Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. PLoS ONE. 11(2). e0148101–e0148101. 23 indexed citations

16.

Borg, David, Charlotta Hedner, Jonna Berntsson, et al.. (2016). Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. Journal of Gastrointestinal Oncology. 7(6). 848–859. 43 indexed citations

17.

Hedner, Charlotta, David Borg, Björn Nodin, et al.. (2016). Prognostic impact of tumor-associated B-cells and plasma cells in esophageal and gastric adenocarcinoma.. Journal of Clinical Oncology. 34(4_suppl). 63–63.

18.

Ansari, Daniel, Bobby Tingstedt, Bodil Andersson, et al.. (2016). Pancreatic Cancer: Yesterday, Today and Tomorrow. Future Oncology. 12(16). 1929–1946. 294 indexed citations

19.

Hedner, Charlotta, Lena Tran, David Borg, et al.. (2015). Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. Histopathology. 68(2). 230–240. 18 indexed citations

20.

Jönsson, Mats, et al.. (2009). Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. BMC Clinical Pathology. 9(1). 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact